Where to Get Retatrutide in 2026: Availability by Source

Is retatrutide available?

No, retatrutide is not commercially available anywhere in the world. As of October 2026, retatrutide (LY3437943) remains an investigational drug; Phase 3 results have been reported and Lilly plans a BLA submission to the FDA in Q1 2027. Eli Lilly has not received approval from the FDA, EMA (European Medicines Agency), MHRA (UK), TGA (Australia), or Health Canada. You cannot get a standard prescription filled at a pharmacy in any country.

The earliest retatrutide could become commercially available is late 2027 or 2028, assuming Phase 3 trials complete successfully and regulatory approvals proceed without delays. This timeline matches the typical drug development pathway: Phase 3 completion → FDA submission → 6-12 month review → approval → commercial manufacturing ramp-up → pharmacy distribution.

Retatrutide availability by country

Retatrutide's regulatory status is the same worldwide: not approved, not commercially available. But the pathways to eventual availability differ by country, as does access to clinical trials.

🇺🇸 United States

• FDA status: Not approved. Phase 3 TRIUMPH results reported; most Phase 3 trials are no longer enrolling. BLA submission planned for Q1 2027.
• Expected approval: 2027-2028 if Phase 3 data replicates Phase 2 results. FDA could grant priority review (6-month timeline) if retatrutide shows significant improvement over existing treatments.
• Current access: Clinical trials where a study is still open (ClinicalTrials.gov) are the main lawful route, alongside Lilly's narrow, physician-requested expanded access program. Compounding pharmacies cannot lawfully supply it (FDA), and research peptides (grey market) are not a legal source.
• Insurance coverage outlook: If approved for type 2 diabetes, most plans will cover it with prior authorization. If approved for obesity only, coverage will be inconsistent. Many insurers still exclude weight management drugs.

🇬🇧 United Kingdom

• MHRA status: Not approved. UK sites participating in global Phase 3 trials.
• Expected approval: MHRA typically follows FDA approval within 6-12 months. If FDA approves in 2027, UK availability could come in late 2027 or early 2028.
• NHS coverage: Even after MHRA approval, NICE (National Institute for Health and Care Excellence) must approve retatrutide for NHS prescribing. This process takes an additional 6-18 months and depends on cost-effectiveness analysis. Tirzepatide (Mounjaro) was MHRA-approved in September 2022 but not NICE-approved for NHS use until March 2023.
• Current access: Clinical trial enrollment, research peptides.

🇪🇺 European Union

• EMA status: Not approved. Phase 3 trials active in Germany, France, Spain, Italy, and other EU countries.
• Expected approval: EMA (European Medicines Agency) reviews in parallel with FDA but often takes 12-18 months after FDA approval. Commercial availability in EU countries likely 2028-2029.
• Country-by-country variation: Even after EMA approval, individual EU countries determine pricing and reimbursement. France, Germany, and the Netherlands typically offer faster access than southern and eastern European countries.
• Current access: Clinical trials at major research hospitals, research peptides (customs enforcement varies).

🇦🇺 Australia

• TGA status: Not approved. Limited Phase 3 trial sites in major cities.
• Expected approval: TGA (Therapeutic Goods Administration) typically approves medications 6-18 months after FDA approval. Australian availability likely 2028.
• PBS coverage: Even after TGA approval, the Pharmaceutical Benefits Scheme (PBS) must approve subsidized access. This process can add 12-24 months. Semaglutide (Ozempic) was TGA-approved in 2019 but not PBS-listed until 2020.
• Current access: Very limited. Clinical trial enrollment (few sites), research peptides (strict customs enforcement, and many shipments are seized).

🇨🇦 Canada

• Health Canada status: Not approved. Phase 3 trials at sites in Ontario, Quebec, and British Columbia.
• Expected approval: Health Canada often reviews in parallel with FDA. Approval could come 6-12 months after US approval (late 2027 or 2028).
• Provincial coverage: Each province makes independent coverage decisions. Public drug plans typically cover diabetes medications but not obesity medications. Private insurance coverage varies.
• Current access: Clinical trials, research peptides.

FDA approval timeline and what it means for availability

The FDA approval process determines when retatrutide becomes commercially available in the US, which then influences international availability. Here's the timeline breakdown:

For complete details on the FDA approval process and TRIUMPH trial program, see our FDA approval status guide.

What could accelerate or delay this timeline

• Priority review: If FDA grants priority review status, the timeline shrinks from 10 months to 6 months. Given retatrutide's superior Phase 2 weight loss data (24.2% vs 15-17% for semaglutide), priority review is possible.
• Breakthrough therapy designation: Retatrutide could receive this status if Phase 3 data shows substantial improvement over existing treatments. This designation provides more frequent FDA guidance and expedited review.
• Safety signals: If Phase 3 trials reveal unexpected adverse events, FDA will require additional safety data, potentially delaying approval by 1-2 years.
• Manufacturing delays: Scaling up production of a triple-agonist peptide is complex. Supply chain issues or quality control problems could delay commercial launch even after FDA approval.
• Cardiovascular outcomes requirement: FDA might require cardiovascular outcomes trial data before approval, which could add 2-3 years. (Tirzepatide was approved without this data, but retatrutide's glucagon component might trigger additional scrutiny.)

How to access retatrutide now (before commercial launch)

While retatrutide isn't commercially available, people are using it today through three main pathways. Only one of them, clinical trials, is lawful. Outside these three, Lilly also runs a narrow expanded access program, described below. This is an overview; for complete details, see our step-by-step guide to getting retatrutide.

1. Clinical trial enrollment (free, pharmaceutical-grade)

The main lawful option for retatrutide access. Eli Lilly's TRIUMPH Phase 3 program includes thousands of participants across multiple trials studying obesity, type 2 diabetes, NASH, and cardiovascular outcomes.

• Cost: Free. Most trials also compensate participants for time and travel.
• Quality: Pharmaceutical-grade retatrutide manufactured under FDA oversight.
• Medical oversight: Regular monitoring, blood work, and clinical assessments throughout the trial.
• Tradeoff: Randomized placebo-controlled trials mean you might receive placebo instead of retatrutide. Most trials don't reveal which group you're in until the study ends.
• Eligibility: Specific BMI requirements, age ranges, and health criteria. You must live near a trial site.
• How to find trials: Search ClinicalTrials.gov or use Eli Lilly's trial finder tool.

The narrow exception: Lilly's expanded access program. Lilly runs an expanded access program for retatrutide before FDA approval, "for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial" (Reuters via KSL). Patients must be 18 or older with a BMI of 35 or more despite tolerating the highest available dose of weight-management therapy, have two or more serious or life-threatening obesity-related complications, be unable to join an ongoing retatrutide (or comparable) trial, and have discussed all standard treatment options, including bariatric surgery, with their doctor (Lilly Medical; ClinicalTrials.gov NCT07629401). The treating physician applies to the FDA as the sponsor of a patient-specific investigational new drug (IND) application and must obtain institutional review board (IRB) approval. Lilly provides the drug at no cost, and direct-to-patient shipping is not available. It is not something a patient can buy.

2. Compounding pharmacies (not a lawful route for retatrutide)

Some compounding pharmacies and telehealth platforms have offered compounded retatrutide, but it is not a lawful option. The FDA states that "Retatrutide and cagrilintide cannot be used in compounding under federal law" (FDA), so neither 503A pharmacies nor 503B outsourcing facilities can lawfully supply it, with or without a prescription. See our compounded retatrutide explainer for the details.

3. Research peptides (grey market, unapproved)

Most retatrutide in circulation comes from research peptide vendors who sell it as "not for human consumption." That label does not make it legal. Peptides are synthesized by labs (mostly in China), vial-filled, and sold without a prescription.

• Cost: $40-120 per 5mg vial. Monthly cost scales with dose; see our detailed cost breakdown.
• Quality: Highly variable. No regulatory oversight. Contamination, underdosing, overdosing, and outright fakes have all been documented.
• Medical oversight: None. You're self-administering an unapproved compound.
• Risk mitigation: Third-party testing (Janoshik or similar labs) is the only quality control. Vet vendors through peptide forums and Reddit communities (r/Peptides, r/retatrutide).
• Legal status: Not a legal source. The FDA has warned companies that illegally sold unapproved drugs containing retatrutide falsely labeled "for research purposes" or "not for human consumption." There's no legal protection for buyers either.

Compounded retatrutide: availability and legal status

Compounding pharmacies have become a major source of GLP-1 medications during semaglutide and tirzepatide shortages. But retatrutide is different: it cannot be lawfully compounded at all.

How drug compounding laws work

The FDA allows compounding pharmacies to produce copies of FDA-approved drugs under specific conditions:

• 503A pharmacies: Traditional state-licensed compounding pharmacies. Can compound patient-specific prescriptions using FDA-approved ingredients. Must be for a specific patient with a prescription from their provider.
• 503B outsourcing facilities: Larger-scale compounding facilities registered with the FDA. Can produce batches of compounded drugs and sell to healthcare facilities. Subject to FDA inspections and quality standards.
• Drug shortage list: The FDA maintains a list of drugs in shortage. During shortages, compounding of those drugs is explicitly permitted. Both semaglutide and tirzepatide appeared on this list during supply constraints in 2022-2024, which is why compounded versions became widely available.

Why retatrutide compounding is different

Retatrutide is not FDA-approved and has never been approved. Unlike semaglutide and tirzepatide (which are approved drugs that happened to be in short supply), retatrutide is an investigational drug. The FDA states that "Retatrutide and cagrilintide cannot be used in compounding under federal law."

Current regulatory stance: The FDA has warned telehealth companies for marketing retatrutide, API distributors for selling it to compounders, and outsourcing facilities for repackaging it. If a pharmacy or telehealth platform offers you compounded retatrutide, it is not a legal product. Clinical trials and Lilly's narrow, physician-requested expanded access program are the lawful ways to receive retatrutide in the US; see our compounded retatrutide explainer.

503A vs 503B for retatrutide: what's the difference?

Bottom line: Neither 503A pharmacies nor 503B outsourcing facilities can lawfully compound retatrutide. Clinical trials and Lilly's narrow, physician-requested expanded access program are the lawful ways to receive it in the US before approval.

What happens after FDA approval: commercial launch and availability

FDA approval is a milestone, but it doesn't mean instant pharmacy availability. Here's what the commercial launch process looks like and how it affects when you can actually get retatrutide.

Manufacturing scale-up (2-4 months post-approval)

Before FDA approval, Eli Lilly will have been manufacturing retatrutide at clinical trial scale. After approval, they need to ramp up to commercial scale, producing millions of doses per month instead of thousands. This takes time:

• Production capacity: Building or converting manufacturing facilities to produce a triple-agonist peptide at scale
• Quality control: Every batch must pass rigorous testing before distribution
• Cold chain logistics: GLP-1 medications require refrigeration throughout the supply chain
• Launch inventory: Eli Lilly will build up 2-3 months of inventory before commercial launch to avoid immediate shortages

Lesson from tirzepatide launch: Mounjaro (tirzepatide for diabetes) was FDA-approved May 2022 but didn't become widely available until late 2022/early 2023. Zepbound (tirzepatide for obesity) launched November 2023 and went into shortage within weeks due to overwhelming demand.

Insurance coverage decisions (6-12 months)

Even after FDA approval and commercial launch, insurance coverage isn't automatic:

• Formulary placement: Each insurance company's pharmacy benefit manager (PBM) decides whether to cover retatrutide and under what conditions. This process takes 3-6 months after approval.
• Prior authorization requirements: Most plans will require documentation that you tried other medications first (step therapy), have a qualifying BMI or A1C, and have medical necessity for retatrutide specifically.
• Diabetes vs obesity coverage: If retatrutide is approved for type 2 diabetes, insurance coverage will be much better than if approved for obesity only. Many plans still exclude weight management drugs entirely.
• Medicare Part D: Currently does not cover obesity medications. Congress has debated changing this, but no legislation has passed as of early 2026.

Manufacturer savings programs

Eli Lilly will almost certainly launch retatrutide with a manufacturer savings card program, similar to the Mounjaro Savings Card that reduced out-of-pocket costs to $25/month for eligible patients.

• Who qualifies: Typically commercial insurance holders only (not Medicare, Medicaid, or uninsured)
• How it works: Present the savings card at pharmacy to reduce copay to $25-50/month (Lilly absorbs the difference)
• Duration: Usually 12-24 months to build market share, then scaled back or eliminated
• Catch: Savings cards are marketing tools. Lilly uses them to establish demand, then scales back once the drug is established

Projected launch pricing

Based on Eli Lilly's pricing for Mounjaro/Zepbound (~$1,060/month list price), retatrutide is expected to launch at $1,000-$1,500/month. As a triple-agonist with superior Phase 2 efficacy data, Lilly can justify a premium. But competitive pressure from oral GLP-1s and other new medications may push pricing lower. See our retatrutide cost guide for detailed projections.

Supply constraints and shortages

Expect shortages. GLP-1 demand has consistently exceeded manufacturer projections. Semaglutide went into shortage in 2022. Tirzepatide went into shortage within months of the Zepbound launch. Retatrutide, with even better weight loss data, will likely face similar demand.

What this means for availability: Even after commercial launch, retatrutide may be difficult to find at pharmacies for the first 6-12 months. Patients who were on it during trials may have priority. New patients may face waitlists or allocation systems.

International regulatory status and global rollout

FDA approval kicks off international regulatory reviews. Here's how the global rollout typically works for new GLP-1 medications:

🇪🇺 EMA (European Medicines Agency)

• Review timeline: EMA often reviews in parallel with FDA but usually approves 6-18 months after FDA.
• Centralized procedure: One EMA approval covers all 27 EU member states plus Iceland, Liechtenstein, and Norway.
• Country-specific decisions: After EMA approval, individual countries negotiate pricing and reimbursement. Germany and France typically move fastest (3-6 months). Southern and eastern European countries can take 12-24 months.
• Projected retatrutide availability in EU: 2028-2029 for most countries.

🇬🇧 MHRA (UK Medicines and Healthcare Products Regulatory Agency)

• Post-Brexit process: UK now reviews independently but often fast-tracks drugs already approved by FDA or EMA.
• Review timeline: Typically 6-12 months after FDA approval.
• NICE appraisal: Even after MHRA approval, the National Institute for Health and Care Excellence (NICE) must approve retatrutide for NHS prescribing. This adds 6-18 months and depends on cost-effectiveness analysis.
• Private prescriptions: Even before NHS coverage, private doctors can prescribe MHRA-approved medications.
• Projected retatrutide availability in UK: MHRA approval 2027-2028, NICE approval 2028-2029.

🇦🇺 TGA (Australia)

• Review timeline: TGA typically approves 6-18 months after FDA, often relying on FDA and EMA safety data.
• PBS listing: Pharmaceutical Benefits Scheme (PBS) listing is separate from TGA approval. PBS determines whether medications are subsidized. The PBAC (Pharmaceutical Benefits Advisory Committee) reviews cost-effectiveness, which can add 12-24 months.
• Private prescription access: TGA-approved medications can be prescribed privately even before PBS listing, but patients pay full price (~$1,000-1,500/month).
• Projected retatrutide availability in Australia: TGA approval 2028, PBS listing 2029-2030.

🇨🇦 Health Canada

• Review timeline: Health Canada often reviews in parallel with FDA. Approval could come 6-12 months after US approval.
• Provincial drug plans: Each Canadian province makes independent coverage decisions. Quebec, Ontario, and British Columbia typically move fastest.
• Private insurance: More likely to cover diabetes indications than obesity indications.
• Projected retatrutide availability in Canada: 2027-2028.

Other regions

• 🇯🇵 Japan (PMDA): Typically 1-2 years after FDA approval. Japanese regulators often require additional domestic clinical trial data.
• 🌎 Latin America: Highly variable. Mexico and Brazil may approve within 12-18 months of FDA. Other countries depend on local regulatory capacity.
• 🌏 Asia-Pacific: Singapore and South Korea typically 12-24 months after FDA. China requires separate clinical trials and approval through NMPA (National Medical Products Administration), which can take 3-5 years.

Retatrutide availability timeline vs tirzepatide and semaglutide

Looking at how long it took semaglutide and tirzepatide to go from Phase 3 trials to widespread availability gives us a realistic expectation for retatrutide.

Semaglutide (Ozempic/Wegovy) Timeline

• Phase 3 trials began: 2015 (SUSTAIN program for diabetes)
• FDA approval (Ozempic for diabetes): December 2017
• Commercial availability: Early 2018
• Wegovy (obesity indication) Phase 3: 2018-2020 (STEP program)
• Wegovy FDA approval: June 2021
• Wegovy commercial launch: September 2021, immediately went into shortage due to overwhelming demand
• Stable widespread availability: Mid-2023 (after Novo Nordisk scaled up manufacturing)

Total time from Phase 3 start to stable availability: About 8 years for diabetes indication, 5 years for obesity indication (but with significant supply constraints).

Tirzepatide (Mounjaro/Zepbound) Timeline

• Phase 3 trials began: 2019 (SURPASS program for diabetes)
• FDA approval (Mounjaro for diabetes): May 2022
• Commercial availability: June 2022, initial supply constraints
• Zepbound (obesity indication) Phase 3: 2020-2022 (SURMOUNT program)
• Zepbound FDA approval: November 2023
• Zepbound commercial launch: December 2023, immediate shortages
• Stable widespread availability: Still not fully stable as of early 2026; intermittent shortages continue

Total time from Phase 3 start to stable availability: About 3 years for diabetes indication, still ongoing for obesity indication.

Projected retatrutide timeline (based on these patterns)

• Phase 3 trials began: 2024 (TRIUMPH program)
• Expected FDA submission: BLA planned for Q1 2027
• Expected FDA approval: 2027-2028
• Expected commercial availability: 2028
• Expected stable widespread availability: 2029-2030 (assuming manufacturing ramp-up and shortage resolution)